Twenty mice with colon cancer were treated with high doses (100 μg EGFR-F-SERS-A dots + 100 μg VEGF-F-SERS-B), another twenty with medium doses (50 μg EGFR-F-SERS-A dots + 50 μg VEGF-F-SERS-B), and the other ten with low doses (25 μg EGFR-F-SERS-A dots + 25 μg VEGF-F-SERS-B) of antibody-conjugated F-SERS dots for the determination of the sensitivity and the identification of the lower dose limit for FRES. Here, VEGFA is linked to colonic neoplasm.